Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Roche Holding AG (GB:0QOK)
LSE:0QOK
Holding GB:0QOK?
Track your performance easily
0QOK Stock Chart & Stats
Day’s RangeCHF0 - CHF0
52-Week RangeCHF212.30 - CHF288.00
Previous CloseCHF250.6
Volume325.99K
Average Volume (3M)262.93K
Market Cap
CHF202.35B
Enterprise ValueCHF224.06B
Total Cash (Recent Filing)CHF7.51B
Total Debt (Recent Filing)CHF25.39B
Price to Earnings (P/E)18.8
Beta0.49
Next Earnings
Jan 30, 2025EPS Estimate
CHF8.39Last Dividend Ex-Date
Mar 14, 2024Dividend Yield3.94%
Share Statistics
EPS (TTM)13.32
Shares Outstanding800,578,845
10 Day Avg. Volume114,436
30 Day Avg. Volume262,930
Standard Deviation0.05
R-Squared0.04
Alpha0.00063
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)3.40
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF276.25Price Target Upside10.23% Upside
Rating ConsensusHold
Number of Analyst Covering11
Roche Holding AG News
Bulls Say, Bears Say
Bulls Say
Clinical ReadoutsRoche will deliver a substantial number of clinical readouts, which can decide a turnaround to the story.
Growth MomentumRoche's strong high-single-digit growth momentum is expected to persist, supported by an updated chart suggesting undervaluation of its pipeline.
Sales And PerformanceThree potential assets are forecasted to generate over $5bn in sales, with Giredestrant for breast cancer showing the highest conviction.
Bears Say
Analyst RatingMaintain Underweight rating ahead of the CT-388/CT-996 data to be presented at the EASD meeting.
Competitive AdvantageData have not shown a clear benefit versus competition, and safety does not seem to provide any advantage.
Research And DevelopmentR&D needs to deliver to make the investment case really attractive.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
10.06% Mutual Funds
0.04% Other Institutional Investors
80.55% Public Companies and
Individual Investors
0QOK FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest share price was CHF212.30 and its highest was CHF288.00 in the past 12 months.
What is Roche Holding AG’s market cap?
Currently, no data Available
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Jan 30, 2025 which is in 36 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jul 25, 2024. The company reported CHF10.23 earnings per share for the quarter, beating the consensus estimate of CHF9.365 by CHF0.865.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Undervalued.
Does Roche Holding AG pay dividends?
Roche Holding AG pays a Annually dividend of CHF9.6 which represents an annual dividend yield of 3.94%. See more information on Roche Holding AG dividends here
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is CHF8.39.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 702,562,700 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of CHF10.23 in its last earnings report, beating expectations of CHF9.365. Following the earnings report the stock price went up 2.25%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in GB:0QOK
---
Company Description
Roche Holding AG
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
---
0QOK Company Deck
---
0QOK Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth in core business areas, significant regulatory achievements, and innovative product launches, particularly in diagnostics and ophthalmology. However, the decline in COVID-related sales and loss of exclusivity posed challenges, alongside some setbacks in clinical trials. Overall, the sentiment leans towards positive due to robust performance in key segments and promising future growth drivers.Read More>---
0QOK Stock 12 Month Forecast
Average Price Target
CHF276.25
▲(10.23% Upside)
Technical Analysis
Best Analysts Covering 0QOK
1 Year
1 Year Success Rate
13/17 ratings generated profit
1 Year Average Return
+10.18%
reiterated a sell rating 5 months ago
Copying Mark Purcell's trades and holding each position for 1 Year would result in 76.47% of your transactions generating a profit, with an average return of +10.18% per trade.
---